Novartis Ag (NVS) Other Non-Current Assets (2009 - 2026)
Novartis Ag (NVS) posted Other Non-Current Assets of $200.0 million for Q1 2026, down 60.71% sequentially from $509.0 million in Q4 2025.
Novartis Ag (NVS) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Novartis Ag (NVS) has 14 years of Other Non-Current Assets data on file, last reported at $200.0 million in Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $200.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (changed N/A YoY) and the FY2025 annual result came in at $509.0 million, down 85.48% from the prior year.
- Other Non-Current Assets declined to $200.0 million in Q1 2026 per NVS's latest filing, from $509.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $4.5 billion in Q2 2025, with the low at $200.0 million in Q1 2026.
- Average Other Non-Current Assets over 5 years is $2.0 billion, with a median of $1.2 billion recorded in 2023.
- Year-over-year, Other Non-Current Assets jumped 303.64% in 2022 and plunged 85.48% in 2025.
- Novartis Ag's Other Non-Current Assets stood at $1.1 billion in 2022, then climbed by 8.02% to $1.2 billion in 2023, then surged by 192.33% to $3.5 billion in 2024, then sank by 85.48% to $509.0 million in 2025, then plunged by 60.71% to $200.0 million in 2026.
- Business Quant data shows NVS's Other Non-Current Assets at $200.0 million in Q1 2026, $509.0 million in Q4 2025, and $4.5 billion in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 777.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200.00 Mn |
| Dec 31, 2025 | 509.00 Mn |
| Jun 30, 2025 | 4.47 Bn |
| Dec 31, 2024 | 3.51 Bn |
| Jun 30, 2024 | 1.66 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Jun 30, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.11 Bn |
| Jun 30, 2022 | 3.89 Bn |
| Dec 31, 2021 | 275.00 Mn |
| Jun 30, 2021 | 2.21 Bn |
| Dec 31, 2020 | 892.00 Mn |
| Sep 30, 2020 | 850.00 Mn |
| Jun 30, 2020 | 866.00 Mn |
| Mar 31, 2020 | 988.00 Mn |
| Dec 31, 2019 | 738.00 Mn |
| Sep 30, 2019 | 689.00 Mn |
| Jun 30, 2019 | 703.00 Mn |
| Mar 31, 2019 | 626.00 Mn |
| Dec 31, 2018 | 895.00 Mn |